THURSDAY, September 17, 2015 • 09:00 AM — 5:35 PM (JST)
The University of Tokyo, Sanjo Kaikan
The Catalent Institute and drug delivery experts from Catalent Pharma Solutions, BASF, Hovione and Qualicaps & Colorcon presented surrounding bioavailability challenges, patient-centric drug design & innovative technologies.
Participants had the opportunity to bring your toughest drug development challenges and discussed with the expert panel.
Registration is closed for this event.
For the agenda in Japanese, please click here.
9:00 AM – 9:30 AM | Registration
9:30 AM – 9:45 AM | Welcome & Introduction
9:45 AM – 10:30 AM | “Improvement of Oral Bioavailability by SNEDDS: Contribution of Lymphatic Transport”
10:30 AM – 11:15 AM | “Bioavailability and Patient-Centric Drug Design Challenges using Hot Melt Extrusion Technology”
11:15 AM – 12:00 PM | “Application of Two-Piece Powder-Filled Hard Capsules in Delivering Inhaled Medications to Patients”
12:00 PM – 1:00 PM | Networking Lunch
1:00 PM – 1:45 PM | “Solid Dispersions: From Development to Commercialization”
1:45 PM – 2:25 PM | “Risk Mitigation of Formulation and Design to Improve Patient Adherence for Solid Oral Dosage Forms”
2:25 PM – 3:15 PM | INAVIR® DRY POWDER INHALER, Formulation/Device Concept and Drug Delivery Performance
3:15 PM – 3:30 PM | BREAK
3:30 PM – 4:10 PM | “Micronization – A Versatile Platform Technology for Bioavailability Enhancement”
4:10 PM – 4:50 PM | “Innovative Protein Improvement Technology: SMARTag”
4:50 PM – 5:25 PM | Expert panel discussion on Emerging Trend in Drug Delivery
5:25 PM – 5:35 PM | Closing Remarks
Cocktail reception at Danwa Hall, 1st Floor at 5:45 PM – 7:20 PM
Dr. Okada is Professor Emeritus of Tokyo University of Pharmacy & Life Sciences (TUPLS) and Director of Okada DDS Research Institute, Inc. Prior to being a professor at TUPLS, Dr. Okada spent 25 years at Takeda Pharmaceutical Co. Ltd. where he led research for devising novel drug delivery systems such as Lupron Depot. He has published 82 peer-reviewed articles, 37 book chapters, and holds 27 U.S. Patents. Dr. Okada has been the recipient of numerous awards including the Award for Drug Research and Development (Pharmaceutical Society of Japan), Imperial Invention Award, CRS/Nagai Innovation Award, Takeru & Aya Higuchi Memorial Prize and Research Achievement Award in Pharmaceutics (Academy of Pharmaceutical Science and Technology, Japan; APSTJ), AFPS/Nagai Distinguished Scientist Award, and Fellow of the CRS. He is an active member of several professional organizations. Dr. Okada serves on the editorial board of the Journal of Controlled Release, was the Former President of the APSTJ and JSPME (Japanese Society of Pharmaceutical Machinery and Engineering. He received his B.S. (1968), M.S. (1970) and Ph.D. (1982) from Kyushu University.
Dr. Higaki has been a Professor of Pharmaceutics in the Faculty of Pharmaceutical Sciences, Okayama University Japan since 2009. His research interests include the analysis and prediction of oral absorption kinetics of drugs, the improvement of oral absorption (solubility, membrane permeability), and enteric nervous system regulation of drug absorption from small intestine. He is the author and/or co-author of more than 140 research papers, reviews and book chapters. He received his Ph.D. in Pharmaceutical Sciences from Kyoto University (1988) and was a post-doctoral fellow at the University of Michigan under the supervision of Professor Gordon Amidon.
Mr. Kishi is leading the technical sales of formulation technologies at BASF Japan since 2011. In his current role, Mr. Kishi advises researchers on BASF’s innovative technologies and products in the area of oral disintegrating tablets and solubilizers. Before joining BASF, he focused on research of oral solid dosages in academic and industry settings. He has leading-edge knowledge on solutions to bioavailability challenges such as spray drying and hot-melt extrusion. In addition to his work at BASF, he is taking a Ph.D. Course for further studies.
Dr. Rajabi-Siahboomi is Vice President and Chief Scientific Officer at Colorcon Inc. He joined Colorcon in 2000 as Technical Director, responsible for Europe, Middle East and Africa. Before joining Colorcon, he has held various academic positions at the University of Nottingham and Liverpool JM University in the UK. His main research interests are in the area of solid dosage form pharmaceutics and pharmaceutical technology with emphasis on oral drug delivery systems. He has published over 250 articles, book chapters, abstracts and patents. He obtained his B.Pharm & Ph.D. in Pharmacy from the University of Nottingham (UK).
Dr. Inoue is a scientist in the Pharmaceutical Technology Division at Daiichi Sankyo. In his current role, Dr. Inoue is the leader of a research team for drug delivery technologies utilizing parenteral administration routes. His main research field is transdermal, nasal and pulmonary drug delivery. During his 27 years in the industry, he completed a year of training in transdermal drug delivery technology at Leiden University in 2002. He graduated from Kyoto University with a master’s degree in 1988, and entered Daiichi Sankyo. In 2012, he received his Ph.D. from Josai University.
Dr. Pinto is the technical lead in Quality-by-design services to optimize and validate commercial manufacturing for clients using Catalent Micron Technologies particle reduction cGMP services. In addition, she provides preformulation and post-formulation trouble-shooting and consulting surrounding API particle reduction technologies. In prior work, Elanor was a Senior Staff Scientist at Ashland and provided technical service and consulting in pharmaceutical formulation development with cellulosics and poly-vinyl polymers and its derivatives. Elanor has authored/co-authored more than 5 scientific papers and book chapters in the field of formulation development and pharmaceutical technology. She has presented several posters and podium presentations at national workshops and meetings. Elanor is the current Chair for the American Association of Pharmaceutical Scientists (AAPS) Modified Release Focus Group. She was the 2012 and 2013 Chair of the Eastern Pharmaceutical Technology Meeting (EPTM). She obtained her Ph.D. from University of Florida’s Pharmaceutics department with her thesis on “Sustained Release of a small lipophilic drug using poly(lactic-co-glycolic) acid (PLGA) polymer microspheres as a drug delivery system for localized delivery.”
Dr. Rabuka assumed the role of Catalent Pharma Solutions’ Global Head of R&D Chemical Biology in October 2014, following Catalent’s acquisition of Redwood Bioscience Inc., where he had previously acted as President and Chief Scientific Officer. Prior to pursuing his Ph.D., Dr. Rabuka worked at the Burnham Institute synthesizing complex glycans and later at Optimer Pharmaceuticals, which he joined as an early employee, focused on the development of glycan and macrolide based antibiotics. Dr. Rabuka graduated with double honors B.S. in Chemistry and Biochemistry from the University of Saskatchewan where he received the Dean’s Science Award and holds a M.S. in Chemistry from the University of Alberta. Dr. Rabuka received a Ph.D. in Chemistry at the University of California, Berkeley as a Chevron Fellow in the lab of Professor Carolyn Bertozzi. His research included developing and applying Redwood’s platform technology to cell surface modification. He is an author on over 20 major publications as well as numerous books chapters and patents.
Dr. Kokubo is currently the R&D Manager at Qualicaps in Japan. Prior to joining Qualicaps, he held various positions at Merck, Japan and was a visiting scientist in the Department of Molecular Neurology at The University of Tokyo. Dr. Kokubo graduated from the Faculty of Agriculture, The University of Tokyo. He holds a Ph.D. in Biostatistics/Biopharmaceutics from the University for Advanced Studies, Japan (Institute of Statistical Mathematics).
Dr. Gaspar is Vice-President and leads the Research & Development Department at Hovione. At Hovione, he led the implementation of spray drying and then directed the R&D group that developed the technology further. He was involved in over 120 projects and was the lead scientist of several projects that reached commercial stage, including the first project at Hovione submitted under Quality by Design. Before becoming a business leader, he was the Director of Drug Product Technologies with responsibility for selection and implementation of new technologies within the company. Before joining Hovione he worked in particle engineering using supercritical fluids. He holds a Ph.D. in Chemical Engineering from the University of Birmingham, UK.
